Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) after taking a closer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE